Evidence supports therapeutic potential of plant-based terpenoids for skin diseases

Evidence supports therapeutic potential of plant-based terpenoids for skin diseases
Credit: Mary Ann Liebert, Inc., publishers

A review of clinical studies that used terpenoids to treat a variety of dermatological diseases demonstrated that this diverse class of phytochemicals may benefit patients with actinic keratosis, cutaneous candidiasis, hyperpigmentation, photoaging, and wounds. Evidence supporting the use of terpenoids in these disorders and linking the significant anti-tumor, anti-inflammatory, and anti-oxidant properties of terpenoids to the pathogenic mechanisms underlying many cutaneous diseases is presented in a Review article published in The Journal of Alternative and Complementary Medicine.

In 'Novel use of terpenoids for treatment of dermatological diseases: a systematic review of clinical trials (http://online.liebertpub.com/doi/full/10.1089/acm.2014.0273)' authors William Tuong and Raja Sivamani, M.D. M.S. CAT, University of California, Davis, and Lauren Walker, University of California Riverside, provide a detailed discussion of promising terpenoids in the area of dermatology and point to the recent approval by the U.S. Food and Drug Administration of ingenol mebutate for the treatment of as an example of the growing clinical relevance of this class of plant-based compounds


Explore further

New drug now available for actinic keratosis

More information: The article is available free on The Journal of Alternative and Complementary Medicine (http://online.liebertpub.com/doi/full/10.1089/acm.2014.0273) website until July 15.
Citation: Evidence supports therapeutic potential of plant-based terpenoids for skin diseases (2015, June 15) retrieved 9 December 2019 from https://medicalxpress.com/news/2015-06-evidence-therapeutic-potential-plant-based-terpenoids.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors

User comments